Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

M. N. Pham, A. B. Apolo, M. De Santis, M. D. Galsky, B. C. Leibovich, L. L. Pisters, A. O. Siefker-Radtke, G. Sonpavde, G. D. Steinberg, C. N. Sternberg, S. T. Tagawa, A. Z. Weizer, M. E. Woods, M. I. Milowsky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Société Internationale d’Urologie and International Consultation on Urological Diseases. Methods: A PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion. Results: The management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients. Conclusions: The management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.

Original languageEnglish (US)
Pages (from-to)367-378
Number of pages12
JournalWorld Journal of Urology
Volume35
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Carcinoma
Neoplasms
Therapeutics
Platinum
Immunotherapy
Drug Therapy
Combination Drug Therapy
PubMed
Urinary Bladder
Referral and Consultation
Retrospective Studies
Clinical Trials
Databases

Keywords

  • Anti-PD-1
  • Anti-PD-L1
  • Chemotherapy
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Targeted therapy
  • Upper tract urothelial carcinoma (UTUC)

ASJC Scopus subject areas

  • Urology

Cite this

Pham, M. N., Apolo, A. B., De Santis, M., Galsky, M. D., Leibovich, B. C., Pisters, L. L., ... Milowsky, M. I. (2017). Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World Journal of Urology, 35(3), 367-378. https://doi.org/10.1007/s00345-016-1885-4

Upper tract urothelial carcinoma topical issue 2016 : treatment of metastatic cancer. / Pham, M. N.; Apolo, A. B.; De Santis, M.; Galsky, M. D.; Leibovich, B. C.; Pisters, L. L.; Siefker-Radtke, A. O.; Sonpavde, G.; Steinberg, G. D.; Sternberg, C. N.; Tagawa, S. T.; Weizer, A. Z.; Woods, M. E.; Milowsky, M. I.

In: World Journal of Urology, Vol. 35, No. 3, 01.03.2017, p. 367-378.

Research output: Contribution to journalArticle

Pham, MN, Apolo, AB, De Santis, M, Galsky, MD, Leibovich, BC, Pisters, LL, Siefker-Radtke, AO, Sonpavde, G, Steinberg, GD, Sternberg, CN, Tagawa, ST, Weizer, AZ, Woods, ME & Milowsky, MI 2017, 'Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer', World Journal of Urology, vol. 35, no. 3, pp. 367-378. https://doi.org/10.1007/s00345-016-1885-4
Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL et al. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World Journal of Urology. 2017 Mar 1;35(3):367-378. https://doi.org/10.1007/s00345-016-1885-4
Pham, M. N. ; Apolo, A. B. ; De Santis, M. ; Galsky, M. D. ; Leibovich, B. C. ; Pisters, L. L. ; Siefker-Radtke, A. O. ; Sonpavde, G. ; Steinberg, G. D. ; Sternberg, C. N. ; Tagawa, S. T. ; Weizer, A. Z. ; Woods, M. E. ; Milowsky, M. I. / Upper tract urothelial carcinoma topical issue 2016 : treatment of metastatic cancer. In: World Journal of Urology. 2017 ; Vol. 35, No. 3. pp. 367-378.
@article{67757a3381ac423a93f4f45a2bb6af44,
title = "Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer",
abstract = "Purpose: To review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Soci{\'e}t{\'e} Internationale d’Urologie and International Consultation on Urological Diseases. Methods: A PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion. Results: The management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients. Conclusions: The management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.",
keywords = "Anti-PD-1, Anti-PD-L1, Chemotherapy, Immune checkpoint inhibitors, Immunotherapy, Targeted therapy, Upper tract urothelial carcinoma (UTUC)",
author = "Pham, {M. N.} and Apolo, {A. B.} and {De Santis}, M. and Galsky, {M. D.} and Leibovich, {B. C.} and Pisters, {L. L.} and Siefker-Radtke, {A. O.} and G. Sonpavde and Steinberg, {G. D.} and Sternberg, {C. N.} and Tagawa, {S. T.} and Weizer, {A. Z.} and Woods, {M. E.} and Milowsky, {M. I.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00345-016-1885-4",
language = "English (US)",
volume = "35",
pages = "367--378",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Upper tract urothelial carcinoma topical issue 2016

T2 - treatment of metastatic cancer

AU - Pham, M. N.

AU - Apolo, A. B.

AU - De Santis, M.

AU - Galsky, M. D.

AU - Leibovich, B. C.

AU - Pisters, L. L.

AU - Siefker-Radtke, A. O.

AU - Sonpavde, G.

AU - Steinberg, G. D.

AU - Sternberg, C. N.

AU - Tagawa, S. T.

AU - Weizer, A. Z.

AU - Woods, M. E.

AU - Milowsky, M. I.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: To review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Société Internationale d’Urologie and International Consultation on Urological Diseases. Methods: A PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion. Results: The management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients. Conclusions: The management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.

AB - Purpose: To review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Société Internationale d’Urologie and International Consultation on Urological Diseases. Methods: A PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion. Results: The management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients. Conclusions: The management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.

KW - Anti-PD-1

KW - Anti-PD-L1

KW - Chemotherapy

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Targeted therapy

KW - Upper tract urothelial carcinoma (UTUC)

UR - http://www.scopus.com/inward/record.url?scp=84976330400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976330400&partnerID=8YFLogxK

U2 - 10.1007/s00345-016-1885-4

DO - 10.1007/s00345-016-1885-4

M3 - Article

C2 - 27342991

AN - SCOPUS:84976330400

VL - 35

SP - 367

EP - 378

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -